

1 **Single Stage Autologous Cartilage Repair Results in Positive Patient Reported Outcomes**
2 **For Chondral Lesions of the Knee: A Systematic Review**

3
4 **ABSTRACT**

5 **Aim:** To perform a systematic review of the clinical literature regarding the efficacy of single stage
6 autologous cartilage repair.

7
8 **Methods:** A systematic review of the literature was performed using PubMed, Scopus, Web of
9 Science, and the Cochrane Library. Preferred Reporting Items for Systematic Reviews and Meta-
10 Analyses guidelines were followed.

11
12 **Results:** Twelve studies were identified; however, due to overlapping patient cohorts, nine studies
13 were included for data extraction and analysis. Six studies applied minced cartilage, while three
14 studies utilized enzymatically processed cartilage. Two authorship groups described single stage
15 techniques that exclusively utilized cartilage from the debrided lesion rim, while the remaining
16 groups either utilized healthy cartilage or combined healthy cartilage with cartilage debrided from
17 lesion rim. Among the included techniques, scaffold augments were used in four studies, and three
18 studies implemented bone autograft augmentation. When summarizing patient reported outcome
19 measures for the included studies, single stage autologous cartilage repair demonstrated an average
20 improvement ranging from 18.7 ± 5.3 to 30.0 ± 8.0 amongst the KOOS subsections, 24.3 ± 10.5
21 for the IKDC subjective score, and 41.0 ± 10.0 for VAS-pain.

22

23 **Conclusion:** Single stage autologous cartilage repair is a promising technique with positive
24 clinical data to date. The current study highlights the overall improvement in patient reported
25 outcomes after repair for chondral defects to the knee with average follow-up ranging from 12 to
26 201 months and also the heterogeneity and variability of the single stage surgical technique.
27 Further discussion on the standardization of practices for a cost-effective single stage augmented
28 autologous cartilage technique is needed. In the future, a well-designed randomized controlled trial
29 is needed to explore the efficacy of this therapeutic modality relative to established intervention.

30
31 **Level of Evidence:** Systematic review; Level IV

32
33 **Key words:** Single stage autologous cartilage repair, chondral lesions, knee, minced cartilage

34
35 **What is already known**

- 36 • Third generation, two stage autologous chondrocyte implantation has shown good clinical
37 outcomes in the treatment of chondral lesions of the knee. However, drawbacks do exist
38 including the cost and potential risks of two procedures.

39 **What are the new findings**

- 40 • Among the studies reviewed there is significant heterogeneity between the techniques used
41 for single stage autologous cartilage repair for chondral lesions of the knee.
- 42 • Single stage augmented autologous cartilage repair is a viable and promising therapeutic
43 intervention for the management of medium sized chondral defects of the knee.

44

45 INTRODUCTION

46 Large chondral defects of the knee can cause debilitating symptoms and eventual joint
47 degradation if left untreated (1). Various cartilage restoration procedures have been proposed with
48 the goal of providing pain relief and improved function. Among these, third generation matrix-
49 induced autologous chondrocyte implantation (ACI) is a popular cell-based treatment modality
50 that has shown positive mid-to-long-term clinical outcomes in the management of chondral defects
51 of the knee (2). It is a two stage procedure that is based on harvesting a patient's cartilage during
52 the first stage and then seeding a three-dimensional matrix scaffold with cultured autologous
53 chondrocytes for subsequent reimplantation (2). Despite promising clinical outcomes, two stage
54 ACI has several major drawbacks. High costs, technical/logistical complexity of the two stage
55 procedure, federal regulatory restrictions, and two postoperative recoveries represent significant
56 limitations to the widespread effectiveness, feasibility, and implementation of this technique (3, 4,
57 5).

58
59 Due to these limitations, recent investigations have focused on the application of single
60 stage cartilage restoration techniques, including enzymatic preparation and mincing. Broadly,
61 enzymatic preparation involves the rapid isolation of chondrocytes, with or without their
62 pericellular matrix (chondrons), from cartilage samples whereas mincing refers to the mechanical
63 degradation of cartilage (6, 7). To date, clinical research has demonstrated sustainable
64 improvement in patient-reported outcome scores with minimal adverse events in patients
65 undergoing single stage procedures at 24 and 60-month follow-up (6, 7). Furthermore, the single
66 stage approach foregoes the expensive chondrocyte culturing phase and need for a second
67 reimplantation surgery, resulting in greater cost-effectiveness (8). Overall, recent clinical evidence

68 suggests that single stage cartilage restoration procedures may be safe, clinically effective, and
69 economical alternatives to conventional two stage procedures. Therefore, the purpose of the
70 present study was to review the literature reporting clinical outcomes of single stage augmented
71 autologous cartilage repair.

72

73 **METHODS**

74 **Article Identification and Selection**

75 This study was conducted in accordance with the 2020 PRISMA (Preferred Reporting
76 Items for Systematic Reviews and Meta-Analyses) guidelines (9). In May of 2021, a literature
77 search for studies related to single stage augmented autologous cartilage repair was performed
78 using PubMed, Scopus, Web of Science, and the Cochrane Library. The following search terms
79 were used: “single stage autologous chondrocyte” OR “single treatment autologous chondrocyte”
80 OR “one stage autologous chondrocyte” OR “one treatment autologous chondrocyte” OR
81 “autologous minced cartilage” OR “paste grafting cartilage.” The inclusion criteria were as
82 follows: autologous cartilage that is mechanically or enzymatically processed, one stage
83 procedure, treated chondral lesions of the knee, English language, primary clinical study with
84 patient reported outcomes, published in 2011 or later to examine current techniques, and a level of
85 evidence IV or better. Exclusion criteria were as follows: any two-stage procedure, allogenic
86 cartilage, any cadaveric/animal/in vitro study, any editorial article, any survey, any letter to the
87 editor, any special topics, and any expert reviews.

88

89 Two independent authors (S.P.D. and L.M.F.) reviewed abstracts and performed a
90 subsequent full-text review for all identified articles. Due to the high likelihood of overlapping

91 patient cohorts in multiple publications, any study by the same authorship group that had the
92 potential to represent the same patients in two or more separate studies was flagged. For these
93 flagged studies, only the most recent study with the longest mean final follow-up was included for
94 data extraction.

95

96 **Data Extraction and Analysis**

97

98 Data was extracted in a standardized fashion into a customized spreadsheet. Data that was
99 extracted included first author, year, study design, total number of patients, number of male
100 patients, number of female patients, average age in years at time of surgery, average lesion size
101 (cm²), average final follow-up in months, patient reported outcome measures (PROMs), presence
102 of radiological outcomes/observations, presence of second look arthroscopy observations/biopsies,
103 membrane used, Knee Injury and Osteoarthritis Outcome Scores (KOOS) outcome scores,
104 International Knee Documentation Committee (IKDC) subjective outcome scores, and Visual
105 Analogue Scale-Pain scores (VAS-pain). Additional data regarding the surgical technique was also
106 extracted. This included the processing system used, cartilage source, concomitant procedures,
107 augmentation, and surgical technique description. Additionally, for manuscripts where data was
108 not reported explicitly in the tables/text, outcomes were extracted from the figures provided by the
109 original authors.

110

111 Studies were designated a level of evidence using the classification system described by
112 Wright et al. (10). Bias analysis was performed by two authors (E.M.P., and B.K.) on studies

113 included for data extraction. The MINORS score was utilized for non-randomized studies (11).
114 The Cochrane-risk-of-bias tool was utilized for randomized studies (12).

115

116 **RESULTS**

117 **Study Selection**

118 A total of 1311 records were identified (**Figure 1**). After the removal of duplicates, 884
119 records were screened by abstract and title, and 848 records were excluded. Full text eligibility
120 was assessed for 36 studies, and 12 studies were included (**Table 1**). Of the 12 studies, three studies
121 had an overlapping patient cohort in a subsequent publication by the same authorship group. Thus,
122 only nine studies were included for final data extraction.

123

124 Bias analysis was performed using the MINORS criteria for eight studies utilizing single
125 stage augmented autologous cartilage repair techniques (range: 8-18). The Cochrane-risk-of-bias
126 tool was utilized for one randomized controlled trial utilizing a single stage augmented autologous
127 cartilage repair technique. This latter study had an overall low risk of bias (13). The results of the
128 bias analysis are presented in **Tables 2 and 3**.

129

130 **Study Characteristics and Demographics**

131 **Table 1** outlines detailed study characteristics for the included single stage augmented
132 autologous cartilage repair studies. Among the nine studies that were selected for data extraction,
133 a total of 240 patients were involved. The patients had a median age of 32 years (range: 24.2-45.3
134 years), a median final follow-up of 28.2 months (range: 12-201 months), and a median lesion size
135 of 2.7 cm² (range: 2.1-3.2 cm²).

136

137 [Insert Figure 1]

138

139 [Insert Table 1]

140

141 [Insert Table 2]

142

143 [Insert Table 3]

144

145 **Single Stage Augmented Autologous Cartilage Repair Surgical Techniques**

146 The single stage augmented autologous cartilage repair surgical techniques included in this
147 study are outlined in **Table 4**. These techniques were broadly categorized by the mechanism of
148 cartilage processing. Three authorship groups reported on the use of enzymatic degradation, while
149 six authorship groups reported on the use mechanical processing techniques.

150

151 Saris et al. utilized an enzymatic single stage chondron implantation technique termed
152 IMPACT (Instant MSC Product Accompanying Autologous Chondron Transplantation) (14, 15,
153 16). This system involves recycling debrided articular cartilage from the lesion rim through a rapid
154 enzymatic isolation protocol to isolate chondrons, which are then combined in a 10:90 or 20:80
155 ratio with allogenic bone marrow derived mesenchymal stem cells (MSCs) using fibrin glue prior
156 to application within the defect. Slynarski et al. utilized a similar technique termed CartiONE (17).
157 This technique involves combining healthy biopsied cartilage with cartilage from the debrided
158 lesion rim. These two sources are then mixed with bone marrow aspirate concentrate that is

159 harvested from the iliac crest. This mixture is enzymatically processed intraoperatively to isolate
160 chondrocytes and bone marrow mononucleated cells (MNCs) prior to seeding onto a load-bearing
161 PolyActive; PolyVation BV cylindrical scaffold. The final orthobiologics construct is then secured
162 to the articular defect using fibrin glue. The third enzymatic technique was performed by Tseng et
163 al. (18, 19), in which both healthy and debrided cartilage are harvested and minced using a tissue
164 pulverizer. The sample is then processed for 20 minutes with collagenase (Librase, Roche,
165 Germany) and added to a specialized biphasic cylindrical scaffold, which is composed of a deeper
166 polylactic-co-glycolic acid tricalcium phosphate component that was designed to sit in the
167 subchondral bone and a superficial polylactic-co-glycolic acid component that was designed to
168 integrate with the surrounding articular cartilage. This biphasic orthobiologics construct is then
169 press fit into the chondral defect.

170

171 Of the remaining studies, there were five different mechanical processing techniques
172 utilized for single stage augmented autologous tissue-based cartilage repair. A 2011 study by Cole
173 et al. utilized the Cartilage Autograft Implantation System (CAIS, DePuy Mitek, Raynham, MA)
174 (13). This technique consists of harvesting healthy hyaline cartilage from a low weight-bearing
175 surface and morselizing the sample. The processed cartilage is then distributed onto a
176 biodegradable scaffold consisting of 35% polycaprolactone and 65% polyglycolic acid with
177 polydioxone mesh reinforcement. The construct is then placed into the chondral defect and secured
178 using biodegradable staple anchors. Two groups described a “paste grafting” technique where
179 healthy cartilage from the intercondylar notch is harvested and combined with cancellous bone
180 autograft from the proximal tibia (20, 21, 22, 23, 24, 25). Together, the bone and cartilage is
181 morselized into a paste using a graft impactor (DePuy, Warsaw, IN) and applied to the defect (24).

182 In 2015, Christensen et al. described a similar mincing technique augmented with bone autograft
183 (26). Cancellous autologous bone is harvested from the proximal tibia, broken down into
184 fragments, and press-fit into the subchondral bony defect. Healthy cartilage is then harvested from
185 the femoral trochlea, manually chipped into fragments, and distributed over the autologous bone
186 graft to fill the cartilage defect. In 2019, Massen et al. described a separate technique where minced
187 cartilage is combined with a Chondro-Gide scaffold (Geistlich Pharma, Princeton, NJ) and secured
188 into the defect with fibrin glue (27). The final technique was described by Cugat et al. in 2020
189 (28). The authors utilized the CN-Biomatrix technique, where healthy hyaline cartilage is
190 harvested from the edges of the chondral defect, while whole blood is spun in a centrifuge to
191 extract plasma rich in growth factors (PRGF). After mechanical degradation, the particulated
192 articular cartilage is combined with PRGF to form a semisolid matrix that is then evenly distributed
193 over the chondral defect.

194

195 When summarizing these single stage techniques based on the harvesting site, two
196 authorship groups described single stage techniques that exclusively utilized cartilage from the
197 debrided lesion rim (14, 15, 16, 28). Massen et al. utilized healthy cartilage from the intercondylar
198 notch or cartilage from the debrided lesion rim (27). Stone et al. and Di Martino et al. described
199 techniques that harvested healthy autologous cartilage from the intercondylar notch, while Cole et
200 al. utilized healthy cartilage from the intercondylar notch or trochlear ridge (21, 22). Christensen
201 et al. harvested healthy cartilage from non-weight bearing portions of the femoral trochlea (26).
202 Slynarski et al., Tseng et al., and Chiang et al. described two separate techniques that combined
203 healthy cartilage from low-load bearing regions of the femoral condyle with cartilage debrided
204 from the lesion rim (17, 18, 19).

205

206 In terms of augmentation, scaffolds were used in four studies. Cole et al. reported the use
207 of a 35% polycaprolactone and 65% polyglycolic acid with polydioxanone mesh reinforcement
208 (13). Massen et al. utilized a Chondro-Gide scaffold (Geistlich Pharma, Princeton, NJ), while
209 Tseng et al. utilized a unique biphasic cylindrical scaffold composed of a superficial polylactic-
210 co-glycolic acid (PCGA) and a deeper PCGA-tricalcium phosphate component.(18, 19, 27)
211 Slynarski et al. utilized a PolyActive; PolyVation BV scaffold composed of polyethylene glycol
212 terephthalate and polybutylene terephthalate (17). Slynarski et al. also supplemented their
213 orthobiologics construct with bone marrow mononucleated cells (MNCs) derived from bone
214 marrow aspirate concentrate (BMAC). Cugat et al. was the only group to utilize a blood derived
215 augment and combined mechanically degraded cartilage with plasma rich in growth factor to form
216 the semisolid CN-Biomatrix scaffold (28). Saris et al. utilized allogenic donor bone marrow
217 derived mesenchymal stem cells (MSCs) (14). Bone autograft augmentation was utilized in 3
218 studies (21, 22, 26).

219 [Insert Table 4]

220

221 **Patient Reported Clinical Outcomes**

222 Three major patient reported outcomes were collected in this study. These were the KOOS,
223 the IKDC and the VAS-pain scores. Among the studies included for data extraction, five studies
224 reported on KOOS scores for single stage augmented cartilage repair. This included 112 patients
225 with a median final follow-up of 24 months (range: 12-61 months). There was an improvement
226 from baseline of 18.7 ± 5.3 for the KOOS-Symptoms subsection, 20.0 ± 6.6 for the KOOS-Pain
227 subsection, 19.9 ± 6.1 for the KOOS-Activities of Daily Living (ADL) subsection, 29.4 ± 9.5 for

228 the KOOS-Sports subsection, and 30.0 ± 8.0 for the KOOS-Quality of Life (QOL) subsection
229 (**Table 5**). Six studies exploring the single stage augmented cartilage repair technique utilized the
230 IKDC subjective survey (**Table 6**). This included 169 patients with a median final follow-up of 24
231 months (range: 12-201 months). The weighted mean for improvement in IKDC scores from
232 baseline was 24.3 ± 10.5 . Four single stage augmented cartilage repair studies reported VAS-pain
233 outcomes (**Table 7**). There was a total of 117 patients with a median final follow-up of 26.1 months
234 (range: 15.9-61 months). The weighted mean improvement in the VAS-pain outcome measure was
235 41.0 ± 10.0 .

236

237

238 [Insert Table 5]

239

240 [Insert Table 6]

241

242 [Insert Table 7]

243

244 **DISCUSSION**

245 The main findings of this systematic review were the following: 1) significant
246 heterogeneity exists across the single stage augmented autologous cartilage repair studies in terms
247 of harvesting site, processing methods, augmentation, and surgical techniques; and 2) single stage
248 augmented autologous cartilage repair procedures demonstrate an average improvement ranging
249 from 18.7 ± 5.3 to 30.0 ± 8.0 amongst the KOOS subsections, 24.3 ± 10.5 for the IKDC subjective
250 score, and 41.0 ± 10.0 for VAS-pain.

251

252 Third generation two stage ACI is a proven and effective treatment modality for the
253 management of large symptomatic chondral defects of the knee. While effective, there are several
254 significant drawbacks to the widespread implementation of two stage ACI, including the cost,
255 logistics and post-operative rehabilitation related to two surgical procedures (3-5). Consequently,
256 a variety of single stage augmented autologous cartilage repair techniques have gained popularity
257 over the past 10 years. In this systematic review, the authors identified a total of twelve studies
258 that investigated outcomes from single stage treatment options using autologous cartilage for the
259 treatment of chondral lesions in the knee; nine of these studies utilized unique patient cohorts and
260 were included for data extraction.

261

262 The benefits of restorative treatment options such as MACI and single stage augmented
263 autologous cartilage repair lay in their use of cell-based therapy and the chondrocyte's capacity to
264 produce tissue that is similar to native hyaline cartilage (29). These cartilage repair techniques
265 utilize the ability of chondrocytes to synthesize type II collagen, proteoglycan, and chondroitin

266 sulfate in order to approximate physiologic cartilage (30). Moreover, there is substantial evidence
267 that suggests positive clinical and histological outcomes for patients treated with two stage ACI or
268 single stage augmented autologous cell-based cartilage repair with studies reporting positive
269 clinical outcomes with up to five-year follow-up (14, 17, 18, 24, 31). Additionally, unlike
270 autografts, cell-based therapy has minimal donor site morbidity, particularly for the management
271 of medium to large chondral defects (32).

272
273 Among the single stage techniques included, there were two broadly different cartilage
274 repair techniques: 1) enzymatically processed cartilage and 2) mechanically minced cartilage
275 (**Table 4**). Of the 12 single stage studies included, three reported the use of enzymatic preparation
276 protocols (14, 17, 18). All three of these studies reported positive clinical post-operative outcomes,
277 and despite the contrast in specifics of each technique, all three studies measured KOOS scores
278 and reported improvements in each subsection. Six of the nine authorship groups using single stage
279 procedures utilized mechanical degradation of autologous cartilage prior to implantation (13, 21,
280 22, 26, 27, 28). Mechanically processed cartilage has several inherent benefits over enzymatic
281 preparation techniques. While many of these benefits are technical, cost-based, or practical, there
282 is also sufficient pre-clinical data to support the efficacy of mechanical preparation techniques. In-
283 vivo and in-vitro studies have suggested that mincing of cartilage allows for potent chondrocyte
284 activation via fragmentation (33). Thus, mechanical processing of a cartilage autograft leads to
285 outgrowth, proliferation, and differentiation of biologically activated primary chondrocytes (33).
286 This potent outgrowth allows for minced cartilage to fill a defect 10 times larger than the biopsy
287 itself (34). Additionally, optimized tissue engineering constructs can be designed by seeding these
288 chondrocytes embedded in their intact native surrounding matrixes inside scaffolds with or without

289 other orthobiologic augments (34). Moreover, in-vitro studies have even suggested that minced
290 cartilage has a more favorable potential for cell proliferation and matrix production relative to
291 chondrocytes that were isolated by enzymatic treatment (35). While limited, the initial clinical
292 reports of single stage mechanically processed autologous cartilage repair techniques have shown
293 good translational efficacy.

294

295 To date, the highest quality single stage study was performed by Cole et al. in 2011 (13). The
296 authors randomized 29 patients into receiving either microfracture or CAIS. At two-year follow-
297 up, the authors reported an improvement in IKDC scores for the CAIS group that was statistically
298 superior relative to the improvement reported by the microfracture group. Additionally, there was
299 no difference in the number of adverse events reported in each group, suggesting that the CAIS
300 technique is a safe and effective method for treating chondral defects of the knee.

301

302 Although current literature lacks other high quality comparative studies between single stage
303 autologous cartilage repair and alternative techniques, it is possible to qualitatively take the clinical
304 outcomes in the present review in the context of prior cartilage studies. The improvement from
305 baseline observed in all KOOS subscales and IKDC following single stage autologous repair
306 exceed previously reported minimal clinically important differences (MCID) thresholds for ACI,
307 as published in a study by Ogura et al. (37). Future studies aimed at establishing clinically
308 significant outcomes specific to single stage autologous techniques are warranted.

309

310

311 **LIMITATIONS**

312 Despite the overall promising results from our systematic review, there exist several
313 important limitations. First, there exists significant heterogeneity between the various single-stage
314 cartilage repair techniques beyond just enzymatic preparation and mincing. These include the
315 presence or absence of additional biologic adjuvants and scaffolds, the manufacturer of the system
316 used, the use of fibrin glue, the source and amount of cartilage used, duration of follow-up,
317 functional outcome scores reported, study design, as well as numerous other factors. As such, the
318 currently available literature precludes accurately pooling functional outcomes data with
319 subsequent statistical-based comparisons. Secondly, the majority of the nine studies analyzing
320 single stage techniques reported observational data in the form of case series (Level IV evidence).
321 Only one single stage study was a randomized control trial that directly compared outcomes to a
322 microfracture control (13). Finally, due to the relative lack of randomized and comparative data
323 relative to more established cartilage repair techniques, it was not possible to pursue a meta-
324 analysis that directly compare single-stage procedures to two stage ACI. While these limitations
325 exist, the results from this study are overall promising and suggest that single stage augmented
326 autologous cartilage repair techniques are viable therapeutic interventions with potential logistical
327 and cost benefits for the management of chondral lesions of the knee.

328 CONCLUSION

329 Single stage autologous cartilage repair is a promising technique with positive clinical data
330 to date. The current study highlights the overall improvement in patient reported outcomes after
331 repair for chondral defects to the knee with average follow-up ranging from 12 to 201 months and
332 also highlights the heterogeneity and variability in single stage surgical technique. Further
333 discussion on the standardization of practices for a cost-effective single stage augmented
334 autologous cartilage technique is needed. In the future, a well-designed randomized controlled trial
335 is needed to explore the efficacy of this therapeutic modality relative to established interventions.

336

337 **FIGURE LEGENDS**

338 **FIGURE 1: Preferred Reporting Items for Systematic Reviews and Meta-Analyses**

339 **(PRISMA) Flow Diagram for Single Stage Studies**

340 **Figure 1:** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) for

341 Single Stage Augmented Autologous Cartilage Repair

342

Journal Pre-proof

343
344
345

TABLES

TABLE 1: Study Characteristics For Single Stage Augmented Autologous Cartilage Repair for Chondral Lesions of the Knee

Author Year	Study Type	Level of Evidence	Number of Patients	Average Age (years)	Lesion Size (cm ²)	Average Final Follow-Up (months)	PROMs	Included in Data Extraction*
Saris(14) 2021	Prospective Case Series	4	35 (24M, 11F)	36	3.2	61	EuroQol-5D, KOOS, VAS	Yes
Di Martino(36) 2021	Retrospective Cohort with Prospectively Collected Clinical Outcomes	3	12 (9M, 3F)	24.2	2.6	84	IKDC, Tegner	Yes
Cugat(28) 2020	Prospective Case Series	4	15 (14M, 1F)	26.8	2.4	15.9	IKDC, Lequenes index, Lysholm, SF-12, Tegner, VAS, WOMAC,	Yes
Slynarski(17) 2020	Prospective Case Series	4	40 (28M, 12F)	35.2	2.09	24	IKDC, KOOS, VAS	Yes
Tseng(18) 2020	Prospective Case Series	4	9 (6M, 4F) [10 patients included in study, 9 completed follow-up]	27.6	Not Provided	60	KOOS, VAS	Yes
Massen(27) 2019	Retrospectively Registered Case Series with Prospective Follow-up	4	27 (15M, 12F)	28.7	3.1	28.2	NAS	Yes
De Windt*(15) 2017	Prospective Case Series	4	35 (24M, 11F)	36	3.2	18	EuroQol-5D, KOOS, VAS	No
Stone(22) 2017	Retrospective Case Series	4	74 (46M, 28F)	45.3	2.16	201	IKDC, NAS,	Yes

							Tegner, WOMAC	
De Windt*(16) 2016	Prospective Case Series	4	10 (8M, 2F)	26	3.6	12	EuroQol- 5D, KOOS, VAS	No
Christensen(26) 2015	Prospective Case Series	4	8 (5M, 3F)	32	3.1	12	IKDC, KOOS, Tegner	Yes
Chiang*(19) 2013	Prospective Case Series	4	10 (6M, 4F)	27.6	Not Provided	24	KOOS, VAS	No
Cole(13) 2011	Randomized Controlled Trial	2	20 (14M, 6F) [29 total patients, 20 underwent CAIS, 9 underwent MFX]	32.7	2.75	24	IKDC, KOOS	Yes

M = Male, F = Female, AE = Adverse Event, KOOS = Knee Injury and Osteoarthritis Outcome Score, VAS = Visual Analogue Scale, NAS = Numerical Analogue Scale, IKDC = International Knee Documentation Committee Questionnaire, ICRS = International Cartilage Restoration and Joint Preservation Society, WOMAC = Western Ontario and McMaster Universities Osteoarthritis Score, SF-12 = Short Form-12, MRI = Magnetic Resonance Imaging, MOCART = Magnetic Resonance Observation of Cartilage Repair Tissue, OCD = Osteochondral defects

*For situation where there were multiple studies from the same authorship group that included the same population and outcome measures at different final follow-up dates, only the most recent study at final follow-up was included in data extraction and data analysis. These studies with overlapping populations were still presented in Table 1. The study by Chiang et al. was repeated by Tseng et al. with the same patients at later follow-up. The patients in the studies by De Windt et al. in 2016 and 2017 were included in the study by Saris et al. in 2021. As a result, for these cases data was only extracted from Tseng et al. and Saris et al., respectively.








346
347
348
349
350
351
352
353
354
355
356

TABLE 2: MINORS Bias Score for Single Stage Augmented Autologous Cartilage Repair

Author	Year	Title	Study Design	Total Score
Saris	2021	Five-Year Outcome of 1-Stage Cell-Based Cartilage Repair Using Recycled Autologous Chondrons and Allogenic Mesenchymal Stromal Cells: A First-in-Human Clinical Trial	Prospective	11
Di Martino	2021	Osteochondral autograft transplantation versus autologous bone-cartilage paste grafting for the treatment of knee osteochondritis dissecans	Retrospective	18
Cugat	2020	A novel autologous-made matrix using hyaline cartilage chips and platelet-rich growth factors for the treatment of full-thickness cartilage or osteochondral defects: Preliminary results	Prospective	11
Slynarski	2020	Single-Stage Autologous Chondrocyte-Based Treatment for the Repair of Knee Cartilage Lesions: Two-Year Follow-up of a Prospective Single-Arm Multicenter Study	Prospective	12
Tseng	2020	The five year outcome of a clinical feasibility study using a biphasic construct with minced autologous cartilage to repair osteochondral defects in the knee	Prospective	10
Massen	2019	One-Step Autologous Minced Cartilage Procedure for the Treatment of Knee Joint Chondral and Osteochondral Lesions: A Series of 27 Patients With 2-Year Follow-up	Retrospective	12
Stone	2017	Articular cartilage paste graft for severe osteochondral lesions of the knee: a 10- to 23-year follow-up study	Retrospective	8
Christensen	2015	Autologous Dual-Tissue Transplantation for Osteochondral Repair	Prospective	10

357
358359
360

TABLE 3: Cochrane Risk of Bias Tool For Randomized Controlled Trials

		Risk of bias domains					
		D1	D2	D3	D4	D5	Overall
Study	Cole 2011						
Domains:							Judgement
D1: Bias arising from the randomization process.							 Low
D2: Bias due to deviations from intended intervention.							
D3: Bias due to missing outcome data.							
D4: Bias in measurement of the outcome.							
D5: Bias in selection of the reported result.							

361
362

363

TABLE 4: Procedure Description for Single Stage Augmented Autologous Cartilage Repair

Author Year	System	Cartilage Source	Processing Technique	Concomitant Procedures	Augmentation (BMAC, scaffold, MSCs)	Surgical Technique Description
Saris(14) 2021 De Windt(15) 2017 De Windt(16) 2016	IMPACT	Debrided lesion rim	Enzymatically	None	Allogenic donor bone marrow derived MSCs	Debrided cartilage from defect was enzymatically processed to isolated chondrons, which were combined in a ratio of 10:90-20:80 with MSCs, suspended in fibrin glue, and delivered into the defect
Di Martino(21) 2021	Paste Graft	Healthy margin of intercondylar notch	Mechanically	None	Autologous bone graft	Healthy cartilage harvested from the ipsilateral margin of the intercondylar notch + cancellous bone autograft from proximal tibia were morselized into a paste delivered into the defect
Cugat(28) 2020	CN-Biomatrix	Cartilage taken from rim of lesion	Mechanically	None	Plasma rich in growth factors (PRGF)	Healthy cartilage from the rim of the lesion was combined with PRGF prepared using the Endoret® PRGF® system protocol and was placed into defect was Biomatrix scaffold could form
Slynarski(17) 2020	CartiONE	Healthy femoral condyle and debrided lesion	Enzymatically	None	Autologous bone marrow mononucleated cells (MNCs) and Scaffold	Healthy cartilage from a low-load bearing area of the femoral condyle was combined with 14mL of BMAC taken from the ipsilateral iliac crest and chondrocytes and bone marrow mononucleated cells were seeded into a 15 or 18 mm cylindrical scaffold which was press fit into the defect and sealed with fibrin glue
Tseng(18) 2020 Chiang(19) 2013	Collagenase (Librase)	Healthy femoral condyle and debrided lesion	Enzymatically	None	Scaffold	Healthy cartilage was taken from the non-articulating margin of the affected femoral condyle and morselized via a power-driven tissue pulverizer and then further enzymatically dissociated with collagenase before being implanted into a scaffold which was press fit into the defect.
Massen(27) 2019	Minced Cartilage	Intercondylar notch or rim of debrided lesion	Mechanically	Patellar realignments (6), reconstructions of MPFL (4), tibial osteotomies (3), extractions of osteosynthetic material (2), osteosyntheses (2), cancellous bone grafts (2), femoral osteotomy (1), microfracture	Scaffold	Debrided cartilage or cartilage from the healthy low-weight bearing intercondylar notch was minced into paste and used to cover the defect with the addition of either fibrin glue (femoral condyle) or a scaffold (trochlear or patellar)

				(1), and meniscal debridement (1)		
Stone(22) 2017	Paste Graft	Intercondylar notch	Mechanically	Partial meniscectomy (20), meniscus allograft transplantation (19), chondroplasty (17), microfracture (17), autograft ACL reconstruction (8), osteotomy (7), meniscus repair (6), allograft ACL reconstruction (3)	Autologous bone graft	Cartilage autograft with underlying subchondral bone was taken from the ipsilateral intercondylar notch, was morselized into a paste and impacted into the defect
Christensen(26) 2015	Autologous Dual-Tissue Transplantation	Femoral Trochlea	Mechanically	None	Autologous bone graft	Proximal tibia autograft was harvested and press-fit into the bony portion of defect and hyaline cartilage taken from non-weight bearing portion of femoral trochlea was chipped into fragments and applied over the defect with fibrin glue
Cole(13) 2011	CAIS	Intercondylar notch or trochlear ridge	Mechanically	None	Absorbable copolymer foam of 35% polycaprolactone and 65% polyglycolic acid with polydioxone mesh reinforcement	Hyaline cartilage was harvested from the intercondylar notch or trochlear ridge before being minced and dispersed over a scaffold with fibrin sealant. The scaffold was sized to the lesion and secured to the defect with two or more biodegradable staple anchors. The scaffold was secured such that the minced cartilage fragments were facing the subchondral bone.

366
367
368
369

370

371
372
373

Table 5: Knee Injury and Osteoarthritis Outcome Scores (KOOS) for Single Stage Augmented Autologous Cartilage Repair

Study Author Year	Improvement in KOOS Scores				
	Symptoms	Pain	ADL	Sports	QOL
Saris(14) 2021	17.1	17.2	20.5	24.5	28.1
Slynarski(17) 2020	18.9	18.6	19.9	25.3	22.4
Tseng(18) 2020	4.4	8.2	5.7	19.9	35.1
Christensen(26) 2015	26.2	20.1	10.6	33.0	35.0
Cole(13) 2011	24.5	32.8	28.9	48.9	44.4
Weighted Mean (Standard Deviation)	18.7 (± 5.4)	20.0 (± 6.6)	19.9 (± 6.1)	29.4 (± 9.5)	30.0 (± 8.0)

374
375
376
377
378
379
380
381
382
383

Table 5: Improvement in KOOS subsections for 5 studies with 112 patients treated by single stage autologous cartilage repair with a median final follow-up of 24 (12-61) months.

ADL = Activities of Daily Living; QOL = Quality of Life

*Values in black were exact integers provided by study authors. Values in red were not specific numerical integers provided by the respective author; they were extrapolated from the figures provided in the respective study. The distance from the x-axis to the point that represented the mean value for each outcome measure was recorded. This was divided by the distance from the x-axis to the value on the figure that represented a score of 100. This fraction was multiplied by 100 to get a KOOS subsection score. The distance was measured by calculating the number of pixels in a column that was orthogonal to the x axis.

384
385

TABLE 6: International Knee Documentation Committee Subjective Scores (IKDC) for Single Stage Augmented Autologous Cartilage Repair

Study Author Year	Improvement in IKDC Scores
Di Martino(21) 2021	34.2
Cugat(28) 2020	36.1
Slynarski(17) 2020	23.9
Stone(22) 2017	14.4
Christensen(26) 2015	32.2
Cole(13) 2011	43.9
Weighted Mean (Standard Deviation)	24.3 (\pm 10.5)

386
387
388
389

Table 6: Improvement in IKDC scores for 6 studies with 169 patients treated by single stage autologous cartilage repair with a median final follow-up of 24 (12-201) months.

390
391

TABLE 7: Visual Analogue Scores for Pain (VAS) for Single Stage Augmented Autologous Cartilage Repair

Study Author	Decrease in VAS-Pain Scores
Saris(14) 2021	30.6
Cugat(28) 2020	54.0
Slynarski(17) 2020	36.6
Massen [†] (27) 2019	54.0
Weighted Mean (Standard Deviation)	41.0 (± 10.0)

392
393
394
395
396
397
398
399

Table 7: Improvement in 100-point VAS/NAS pain scores over 4 studies with 117 patients treated with single stage autologous cartilage repair at a median final follow-up of 26.1 (15.9-61) months.

[†]Used NAS instead of VAS

*Values in black were exact integers provided by study authors. Values in red were not specific numerical integers provided by the respective author; they were extrapolated from the figures provided in the respective study. The distance from the x-axis to the point that represented the mean value for each outcome measure was recorded. This was divided by the distance from the x-axis to the value on the figure that represented a score of 100. This fraction was multiplied by 100 to get a VAS subsection score. The distance was measured by calculating the number of pixels in a column that was orthogonal to the x axis.


400 REFERENCES

401

- 402 1. Chubinskaya S, Haudenschild D, Gasser S, Stannard J, Krettek C, Borrelli J. Articular
403 Cartilage Injury and Potential Remedies. *J Orthop Trauma*. 2015;29 Suppl 12:S47-52.
- 404 2. Schuette HB, Kraeutler MJ, McCarty EC. Matrix-Assisted Autologous Chondrocyte
405 Transplantation in the Knee: A Systematic Review of Mid- to Long-Term Clinical Outcomes.
406 *Orthopaedic Journal of Sports Medicine*. 2017;5(6):232596711770925.
- 407 3. Everhart JS, Campbell AB, Abouljoud MM, Kirven JC, Flanigan DC. Cost-efficacy of Knee
408 Cartilage Defect Treatments in the United States. *Am J Sports Med*. 2020;48(1):242-51.
- 409 4. Kon E, Filardo G, Di Matteo B, Perdisa F, Marcacci M. Matrix assisted autologous
410 chondrocyte transplantation for cartilage treatment: A systematic review. *Bone Joint Res*.
411 2013;2(2):18-25.
- 412 5. Kon E, Verdonk P, Condello V, Delcogliano M, Dhollander A, Filardo G, et al. Matrix-
413 assisted autologous chondrocyte transplantation for the repair of cartilage defects of the knee:
414 systematic clinical data review and study quality analysis. *Am J Sports Med*. 2009;37 Suppl
415 1:156S-66S.
- 416 6. Saris TFF, de Windt TS, Kester EC, Vonk LA, Custers RJH, Saris DBF. Five-Year Outcome of
417 1-Stage Cell-Based Cartilage Repair Using Recycled Autologous Chondrons and Allogenic
418 Mesenchymal Stromal Cells: A First-in-Human Clinical Trial. *Am J Sports Med*. 2021;49(4):941-7.
- 419 7. Słynarski K, de Jong WC, Snow M, Hendriks JAA, Wilson CE, Verdonk P. Single-Stage
420 Autologous Chondrocyte-Based Treatment for the Repair of Knee Cartilage Lesions: Two-Year
421 Follow-up of a Prospective Single-Arm Multicenter Study. *Am J Sports Med*. 2020;48(6):1327-
422 37.
- 423 8. de Windt TS, Sorel JC, Vonk LA, Kip MMA, Ijzerman MJ, Saris DBF. Early health economic
424 modelling of single-stage cartilage repair. Guiding implementation of technologies in
425 regenerative medicine. *J Tissue Eng Regen Med*. 2017;11(10):2950-9.
- 426 9. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
427 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*.
428 2021:n71.
- 429 10. Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal.
430 *J Bone Joint Surg Am*. 2003;85(1):1-3.
- 431 11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for
432 non-randomized studies (minors): development and validation of a new instrument. *ANZ*
433 *Journal of Surgery*. 2003;73(9):712-6.
- 434 12. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised
435 tool for assessing risk of bias in randomised trials. *Bmj*. 2019;366:l4898.
- 436 13. Cole BJ, Farr J, Winalski CS, Hosea T, Richmond J, Mandelbaum B, et al. Outcomes After
437 a Single-Stage Procedure for Cell-Based Cartilage Repair. *The American Journal of Sports*
438 *Medicine*. 2011;39(6):1170-9.
- 439 14. Saris TFF, De Windt TS, Kester EC, Vonk LA, Custers RJH, Saris DBF. Five-Year Outcome of
440 1-Stage Cell-Based Cartilage Repair Using Recycled Autologous Chondrons and Allogenic

- 441 Mesenchymal Stromal Cells: A First-in-Human Clinical Trial. *The American Journal of Sports*
442 *Medicine*. 2021;49(4):941-7.
- 443 15. De Windt TS, Vonk LA, Slaper-Cortenbach ICM, Nizak R, Van Rijen MHP, Saris DBF.
444 Allogeneic MSCs and Recycled Autologous Chondrons Mixed in a One-Stage Cartilage Cell
445 Transplantation: A First-in-Man Trial in 35 Patients. *STEM CELLS*. 2017;35(8):1984-93.
- 446 16. De Windt TS, Vonk LA, Slaper-Cortenbach ICM, Van Den Broek MPH, Nizak R, Van Rijen
447 MHP, et al. Allogeneic Mesenchymal Stem Cells Stimulate Cartilage Regeneration and Are Safe
448 for Single-Stage Cartilage Repair in Humans upon Mixture with Recycled Autologous Chondrons.
449 *STEM CELLS*. 2016;35(1):256-64.
- 450 17. Słynarski K, De Jong WC, Snow M, Hendriks JAA, Wilson CE, Verdonk P. Single-Stage
451 Autologous Chondrocyte-Based Treatment for the Repair of Knee Cartilage Lesions: Two-Year
452 Follow-up of a Prospective Single-Arm Multicenter Study. *The American Journal of Sports*
453 *Medicine*. 2020;48(6):1327-37.
- 454 18. Tseng T-H, Jiang C-C, Lan HH-C, Chen C-N, Chiang H. The five year outcome of a clinical
455 feasibility study using a biphasic construct with minced autologous cartilage to repair
456 osteochondral defects in the knee. *International Orthopaedics*. 2020;44(9):1745-54.
- 457 19. Chiang H, Liao CJ, Hsieh CH, Shen CY, Huang YY, Jiang CC. Clinical feasibility of a novel
458 biphasic osteochondral composite for matrix-associated autologous chondrocyte implantation.
459 *Osteoarthritis and Cartilage*. 2013;21(4):589-98.
- 460 20. Kon E, Vannini F, Buda R, Filardo G, Cavallo M, Ruffilli A, et al. How to Treat
461 Osteochondritis Dissecans of the Knee: Surgical Techniques and New Trends: AAOS Exhibit
462 Selection. *J Bone Joint Surg Am*. 2012;94(1).
- 463 21. Di Martino A, Silva S, Andriolo L, Merli G, Reale D, Zaffagnini S, et al. Osteochondral
464 autograft transplantation versus autologous bone-cartilage paste grafting for the treatment of
465 knee osteochondritis dissecans. *International Orthopaedics*. 2021;45(2):453-61.
- 466 22. Stone KR, Pelsis JR, Na K, Walgenbach AW, Turek TJ. Articular cartilage paste graft for
467 severe osteochondral lesions of the knee: a 10- to 23-year follow-up study. *Knee Surgery,*
468 *Sports Traumatology, Arthroscopy*. 2017;25(12):3824-33.
- 469 23. Stone KR, Walgenbach A. Surgical technique for articular cartilage transplantation to
470 full-thickness cartilage defects in the knee joint. *Operative Techniques in Orthopaedics*.
471 1997;7(4):305-11.
- 472 24. Stone KR, Walgenbach AW, Freyer A, Turek TJ, Speer DP. Articular Cartilage Paste
473 Grafting to Full-Thickness Articular Cartilage Knee Joint Lesions: A 2- to 12-Year Follow-up.
474 *Arthroscopy: The Journal of Arthroscopic & Related Surgery*. 2006;22(3):291-9.
- 475 25. Stone KR. Articular cartilage paste grafting: Surgical technique and initial results.
476 *European Journal of Sports Traumatology and Related Research*. 1998;20(2):71-9.
- 477 26. Christensen BB, Foldager CB, Jensen J, Lind M. Autologous Dual-Tissue Transplantation
478 for Osteochondral Repair. *CARTILAGE*. 2015;6(3):166-73.
- 479 27. Massen FK, Inauen CR, Harder LP, Runer A, Preiss S, Salzman GM. One-Step Autologous
480 Minced Cartilage Procedure for the Treatment of Knee Joint Chondral and Osteochondral
481 Lesions: A Series of 27 Patients With 2-Year Follow-up. *Orthopaedic Journal of Sports Medicine*.
482 2019;7(6):232596711985377.
- 483 28. Cugat R, Alentorn-Geli E, Navarro J, Cuscó X, Steinbacher G, Seijas R, et al. A novel
484 autologous-made matrix using hyaline cartilage chips and platelet-rich growth factors for the

- 485 treatment of full-thickness cartilage or osteochondral defects: Preliminary results. *Journal of*
486 *Orthopaedic Surgery*. 2020;28(1):230949901988754.
- 487 29. Gillogly SD, Myers TH, Reinold MM. Treatment of full-thickness chondral defects in the
488 knee with autologous chondrocyte implantation. *J Orthop Sports Phys Ther*. 2006;36(10):751-
489 64.
- 490 30. Aldrian S, Zak L, Wondrasch B, Albrecht C, Stelzeneder B, Binder H, et al. Clinical and
491 Radiological Long-term Outcomes After Matrix-Induced Autologous Chondrocyte
492 Transplantation. *The American Journal of Sports Medicine*. 2014;42(11):2680-8.
- 493 31. Pestka JM, Bode G, Salzmann G, Steinwachs M, Schmal H, Südkamp NP, et al. Clinical
494 Outcomes After Cell-Seeded Autologous Chondrocyte Implantation of the Knee. *The American*
495 *Journal of Sports Medicine*. 2014;42(1):208-15.
- 496 32. Marlovits S, Aldrian S, Wondrasch B, Zak L, Albrecht C, Welsch G, et al. Clinical and
497 Radiological Outcomes 5 Years After Matrix-Induced Autologous Chondrocyte Implantation in
498 Patients With Symptomatic, Traumatic Chondral Defects. *The American Journal of Sports*
499 *Medicine*. 2012;40(10):2273-80.
- 500 33. Schneider S, Ossendorff R, Holz J, Salzmann GM. Arthroscopic Minced Cartilage
501 Implantation (MCI): A Technical Note. *Arthroscopy Techniques*. 2021;10(1):e97-e101.
- 502 34. McCormick F, Yanke A, Provencher MT, Cole BJ. Minced articular cartilage--basic
503 science, surgical technique, and clinical application. *Sports Medicine and Arthroscopy Review*.
504 2008;16(4):217-20.
- 505 35. Tsuyuguchi Y, Nakasa T, Ishikawa M, Miyaki S, Matsushita R, Kanemitsu M, et al. The
506 Benefit of Minced Cartilage Over Isolated Chondrocytes in Atelocollagen Gel on Chondrocyte
507 Proliferation and Migration. *CARTILAGE*. 2021;12(1):93-101.
- 508 36. Andriolo L, Reale D, Di Martino A, De Filippis R, Sessa A, Zaffagnini S, et al. Long-term
509 Results of Arthroscopic Matrix-Assisted Autologous Chondrocyte Transplantation: A Prospective
510 Follow-up at 15 Years. *The American Journal of Sports Medicine*. 2020;48(12):2994-3001.
- 511 37. Ogura T, Ackermann J, Barbieri Mestriner A, Merkely G, Gomoll AH. Minimal Clinically
512 Important Differences and Substantial Clinical Benefit in Patient-Reported Outcome Measures
513 after Autologous Chondrocyte Implantation. *Cartilage*. 2020;11(4):412-422.
514 doi:10.1177/1947603518799839
515



Abbreviations

VAS, visual analogue scale

KOOS, knee injury and osteoarthritis outcome score

IKDC, internal knee documentation committee

ACI, autologous chondrocyte implantation

MINORS, Methodological Index for Non-Randomized Studies

PROM, patient reported outcome measure

IMPACT, Instant MSC Product Accompanying Autologous Chondron Transplantation

RCT, randomized controlled trial

MSC, mesenchymal stem cells

MNC, mononucleated cells

CAIS, Cartilage Autograft Implantation System

PRGF, plasma rich in growth factors

ADL, activities of daily living

QOL, quality of life

CT, computed tomography

WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index

SF-12, 12-item short form